Clinical Trials · NCT01149356
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 15
- Start date
- Oct 2010
- Locations
- 4 sites, United States
- Primary endpoint
- Incidence of treatment emergent adverse events (TEAEs) based on CTCAE version 3 grade